Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth

Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical trials for treatment of cancer, obesity, and other diseases. Here, we report a previously unknown mechanism of FASN re...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research (Chicago, Ill.) Vol. 76; no. 23; p. 6924
Main Authors:	Lin, Huai-Peng, Cheng, Zhou-Li, He, Ruo-Yu, Song, Lei, Tian, Meng-Xin, Zhou, Li-Sha, Groh, Beezly S, Liu, Wei-Ren, Ji, Min-Biao, Ding, Chen, Shi, Ying-Hong, Guan, Kun-Liang, Ye, Dan, Xiong, Yue
Format:	Journal Article
Language:	English
Published:	United States 01.12.2016
Subjects:	Acetylation Cell Growth Processes - genetics Cell Proliferation Fatty Acid Synthases - genetics Humans Lipogenesis - genetics Signal Transduction Tumor Microenvironment
ISSN:	1538-7445, 1538-7445
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical trials for treatment of cancer, obesity, and other diseases. Here, we report a previously unknown mechanism of FASN regulation involving its acetylation by KAT8 and its deacetylation by HDAC3. FASN acetylation promoted its degradation via the ubiquitin-proteasome pathway. FASN acetylation enhanced its association with the E3 ubiquitin ligase TRIM21. Acetylation destabilized FASN and resulted in decreased de novo lipogenesis and tumor cell growth. FASN acetylation was frequently reduced in human hepatocellular carcinoma samples, which correlated with increased HDAC3 expression and FASN protein levels. Our results suggest opportunities to target FASN acetylation as an anticancer strategy. Cancer Res; 76(23); 6924-36. ©2016 AACR.
AbstractList	Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical trials for treatment of cancer, obesity, and other diseases. Here, we report a previously unknown mechanism of FASN regulation involving its acetylation by KAT8 and its deacetylation by HDAC3. FASN acetylation promoted its degradation via the ubiquitin-proteasome pathway. FASN acetylation enhanced its association with the E3 ubiquitin ligase TRIM21. Acetylation destabilized FASN and resulted in decreased de novo lipogenesis and tumor cell growth. FASN acetylation was frequently reduced in human hepatocellular carcinoma samples, which correlated with increased HDAC3 expression and FASN protein levels. Our results suggest opportunities to target FASN acetylation as an anticancer strategy. Cancer Res; 76(23); 6924-36. ©2016 AACR.Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical trials for treatment of cancer, obesity, and other diseases. Here, we report a previously unknown mechanism of FASN regulation involving its acetylation by KAT8 and its deacetylation by HDAC3. FASN acetylation promoted its degradation via the ubiquitin-proteasome pathway. FASN acetylation enhanced its association with the E3 ubiquitin ligase TRIM21. Acetylation destabilized FASN and resulted in decreased de novo lipogenesis and tumor cell growth. FASN acetylation was frequently reduced in human hepatocellular carcinoma samples, which correlated with increased HDAC3 expression and FASN protein levels. Our results suggest opportunities to target FASN acetylation as an anticancer strategy. Cancer Res; 76(23); 6924-36. ©2016 AACR. Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical trials for treatment of cancer, obesity, and other diseases. Here, we report a previously unknown mechanism of FASN regulation involving its acetylation by KAT8 and its deacetylation by HDAC3. FASN acetylation promoted its degradation via the ubiquitin-proteasome pathway. FASN acetylation enhanced its association with the E3 ubiquitin ligase TRIM21. Acetylation destabilized FASN and resulted in decreased de novo lipogenesis and tumor cell growth. FASN acetylation was frequently reduced in human hepatocellular carcinoma samples, which correlated with increased HDAC3 expression and FASN protein levels. Our results suggest opportunities to target FASN acetylation as an anticancer strategy. Cancer Res; 76(23); 6924-36. ©2016 AACR.
Author	Zhou, Li-Sha Xiong, Yue Liu, Wei-Ren Groh, Beezly S Ding, Chen Ye, Dan Ji, Min-Biao Shi, Ying-Hong Lin, Huai-Peng Cheng, Zhou-Li Song, Lei Guan, Kun-Liang He, Ruo-Yu Tian, Meng-Xin
Author_xml	– sequence: 1 givenname: Huai-Peng surname: Lin fullname: Lin, Huai-Peng organization: State Key Laboratory of Genetic Engineering, Collaborative Innovation Center of Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China – sequence: 2 givenname: Zhou-Li surname: Cheng fullname: Cheng, Zhou-Li organization: State Key Laboratory of Genetic Engineering, Collaborative Innovation Center of Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China – sequence: 3 givenname: Ruo-Yu surname: He fullname: He, Ruo-Yu organization: State Key Laboratory of Surface Physics and Department of Physics, Fudan University, Shanghai, China – sequence: 4 givenname: Lei surname: Song fullname: Song, Lei organization: State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, National Center for National Center for Protein Science (The PHOENIX Center), Beijing, China – sequence: 5 givenname: Meng-Xin surname: Tian fullname: Tian, Meng-Xin organization: Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China – sequence: 6 givenname: Li-Sha surname: Zhou fullname: Zhou, Li-Sha organization: State Key Laboratory of Genetic Engineering, Collaborative Innovation Center of Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China – sequence: 7 givenname: Beezly S surname: Groh fullname: Groh, Beezly S organization: Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina – sequence: 8 givenname: Wei-Ren surname: Liu fullname: Liu, Wei-Ren organization: Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China – sequence: 9 givenname: Min-Biao surname: Ji fullname: Ji, Min-Biao organization: State Key Laboratory of Surface Physics and Department of Physics, Fudan University, Shanghai, China – sequence: 10 givenname: Chen surname: Ding fullname: Ding, Chen organization: State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, National Center for National Center for Protein Science (The PHOENIX Center), Beijing, China – sequence: 11 givenname: Ying-Hong surname: Shi fullname: Shi, Ying-Hong organization: Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China – sequence: 12 givenname: Kun-Liang surname: Guan fullname: Guan, Kun-Liang email: kuguan@ucsd.edu, yedan@fudan.edu.cn, yxiong@email.unc.edu organization: Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, California – sequence: 13 givenname: Dan surname: Ye fullname: Ye, Dan email: kuguan@ucsd.edu, yedan@fudan.edu.cn, yxiong@email.unc.edu organization: Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China – sequence: 14 givenname: Yue surname: Xiong fullname: Xiong, Yue email: kuguan@ucsd.edu, yedan@fudan.edu.cn, yxiong@email.unc.edu organization: Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/27758890$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtPwzAQhC1URB_wE0A-cknxI46TY9XSUqmCA-Uc2Y5DjBK7xE5R-PUEtUicdrX6ZjUzUzCyzmoAbjGaY8zSB4RQGrGYk7kSNsJJhFnGL8AEM5pGPI7Z6N8-BlPvPwYJw4hdgTHhnKVphiagWmkfhDS1-RbBOAtdCdcihB4ulCnga29DJbyG8vegQ1-fqK2tjDTBw5WGz-7o4M4c3Lu22hsPhS3gvmtcC5e6ruGmdV-hugaXpai9vjnPGXhbP-6XT9HuZbNdLnaRijkPESFK0kRmSvMYJSqhAiMilCgzjUkpBc2EorykTGWqYEkpGRO0UIXiTGJaSjID96e_h9Z9dkO4vDFeDT6E1a7zOU4pizNKYjSgd2e0k40u8kNrGtH2-V875AdLjWt7
CitedBy_id	crossref_primary_10_1002_mco2_261 crossref_primary_10_1002_hep_32045 crossref_primary_10_1186_s13046_022_02583_z crossref_primary_10_1038_s41419_025_07782_y crossref_primary_10_1016_j_addr_2020_07_013 crossref_primary_10_3390_ijms222413437 crossref_primary_10_1111_cas_14836 crossref_primary_10_1007_s00109_021_02082_2 crossref_primary_10_1038_s41598_019_40238_w crossref_primary_10_3390_cancers10110447 crossref_primary_10_3390_ijms24087463 crossref_primary_10_1038_s41388_020_1156_0 crossref_primary_10_1007_s11307_021_01608_x crossref_primary_10_1038_s41392_023_01405_8 crossref_primary_10_3390_cancers12061419 crossref_primary_10_3892_ijo_2017_4000 crossref_primary_10_1186_s40364_024_00681_y crossref_primary_10_1016_j_neurobiolaging_2021_06_019 crossref_primary_10_1371_journal_pgen_1009736 crossref_primary_10_1016_j_mce_2020_111135 crossref_primary_10_1038_s41467_023_44364_y crossref_primary_10_1016_j_metabol_2025_156394 crossref_primary_10_1038_s41598_019_43297_1 crossref_primary_10_1016_j_jlr_2024_100721 crossref_primary_10_3390_cancers15082385 crossref_primary_10_1002_1878_0261_13582 crossref_primary_10_1073_pnas_2212220119 crossref_primary_10_1038_s42255_023_00904_w crossref_primary_10_1002_hep_29562 crossref_primary_10_1111_acel_13491 crossref_primary_10_3390_ijms20071776 crossref_primary_10_1155_2020_7618506 crossref_primary_10_1371_journal_pcbi_1010690 crossref_primary_10_1002_ctm2_70145 crossref_primary_10_1186_s12944_024_02175_0 crossref_primary_10_3389_fonc_2023_1182434 crossref_primary_10_1016_j_biopha_2020_110472 crossref_primary_10_1080_14728222_2022_2077189 crossref_primary_10_1007_s11033_021_06364_3 crossref_primary_10_3389_fgene_2020_572663 crossref_primary_10_7554_eLife_62394 crossref_primary_10_1007_s00018_023_04820_w crossref_primary_10_1016_j_phymed_2025_157170 crossref_primary_10_3390_metabo14060325 crossref_primary_10_1038_s44324_024_00021_6 crossref_primary_10_1038_s41598_019_39778_y crossref_primary_10_1530_JOE_18_0037 crossref_primary_10_1016_j_gene_2023_147574 crossref_primary_10_1038_s41467_023_40975_7 crossref_primary_10_1007_s00441_023_03791_5 crossref_primary_10_1097_HEP_0000000000001429 crossref_primary_10_1007_s00018_023_04965_8 crossref_primary_10_1158_0008_5472_CAN_23_2266 crossref_primary_10_1186_s12967_023_04721_3 crossref_primary_10_1016_j_coisb_2017_05_011 crossref_primary_10_1038_s43018_023_00522_1 crossref_primary_10_1186_s12864_018_5265_x crossref_primary_10_1016_j_ijbiomac_2024_130961 crossref_primary_10_1038_s41467_018_07185_y crossref_primary_10_3390_molecules25173935 crossref_primary_10_1007_s11033_022_08206_2 crossref_primary_10_1016_j_bbadis_2021_166103 crossref_primary_10_1172_JCI184665 crossref_primary_10_1016_j_jff_2021_104857 crossref_primary_10_3390_ijms231911093 crossref_primary_10_1038_s41375_023_02130_5 crossref_primary_10_1038_s41388_019_1015_z crossref_primary_10_1182_blood_2018_05_851667 crossref_primary_10_1038_s41422_020_00443_z crossref_primary_10_1016_j_jnutbio_2024_109678 crossref_primary_10_1016_j_bbadis_2022_166472 crossref_primary_10_1016_j_metabol_2020_154290 crossref_primary_10_1084_jem_20201606 crossref_primary_10_3390_metabo13050647 crossref_primary_10_1186_s40164_023_00394_2 crossref_primary_10_3390_cancers15010023 crossref_primary_10_1186_s12935_023_03143_x crossref_primary_10_1186_s13578_025_01348_3 crossref_primary_10_3389_fonc_2025_1464914 crossref_primary_10_3390_nu15061416 crossref_primary_10_1186_s11658_024_00563_z crossref_primary_10_1186_s13045_022_01340_1 crossref_primary_10_1186_s12915_023_01698_9 crossref_primary_10_3390_life12111769 crossref_primary_10_1038_s41392_021_00825_8 crossref_primary_10_3389_fphys_2020_592689 crossref_primary_10_1038_s41419_023_05582_w crossref_primary_10_3389_fonc_2020_01025 crossref_primary_10_3390_cancers16071313 crossref_primary_10_1016_j_ajpath_2023_08_005 crossref_primary_10_1038_s41417_022_00464_3 crossref_primary_10_1038_s41416_020_0779_9
ContentType	Journal Article
Copyright	2016 American Association for Cancer Research.
Copyright_xml	– notice: 2016 American Association for Cancer Research.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1158/0008-5472.can-16-1597
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1538-7445
ExternalDocumentID	27758890
Genre	Journal Article
GrantInformation_xml	– fundername: NCI NIH HHS grantid: R01 CA163834 – fundername: NIGMS NIH HHS grantid: R01 GM051586 – fundername: NCI NIH HHS grantid: R35 CA196878 – fundername: NIGMS NIH HHS grantid: R01 GM067113
GroupedDBID	--- -ET 18M 29B 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADCOW ADNWM AENEX AETEA AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 EBS ECM EIF EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO NPM OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ 7X8
ID	FETCH-LOGICAL-c477t-22cb36b9ce7406c63a102acaf9e12fba39ac37f35c9cd56fb55a3dcdc75b13fb2
IEDL.DBID	7X8
ISICitedReferencesCount	100
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000389435800018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1538-7445
IngestDate	Fri Sep 05 07:26:37 EDT 2025 Mon Jul 21 05:57:27 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	23
Language	English
License	2016 American Association for Cancer Research.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c477t-22cb36b9ce7406c63a102acaf9e12fba39ac37f35c9cd56fb55a3dcdc75b13fb2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	http://doi.org/10.1158/0008-5472.CAN-16-1597
PMID	27758890
PQID	1835493240
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1835493240 pubmed_primary_27758890
PublicationCentury	2000
PublicationDate	2016-12-01
PublicationDateYYYYMMDD	2016-12-01
PublicationDate_xml	– month: 12 year: 2016 text: 2016-12-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Cancer research (Chicago, Ill.)
PublicationTitleAlternate	Cancer Res
PublicationYear	2016
References	15050917 - Cancer Cell. 2004 Mar;5(3):253-61 17882277 - Nat Rev Cancer. 2007 Oct;7(10):763-77 8640795 - Cancer Res. 1996 Mar 15;56(6):1189-93 19635858 - J Exp Med. 2009 Aug 3;206(8):1661-71 18641315 - J Immunol. 2008 Aug 1;181(3):1780-6 17956988 - Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17335-40 10962028 - Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10619-24 26468325 - Sci Transl Med. 2015 Oct 14;7(309):309ra163 15880754 - J Pathol. 2005 Jun;206(2):214-9 10095788 - Eur J Biochem. 1999 Mar;260(2):505-11 23297220 - Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52 15627654 - J Lipid Res. 2005 Apr;46(4):697-705 26942676 - Mol Cell. 2016 Mar 3;61(5):720-33 22902405 - Cell Rep. 2012 Aug 30;2(2):419-31 11064454 - Oncogene. 2000 Oct 26;19(45):5173-81 23932781 - Mol Cell. 2013 Aug 22;51(4):506-18 22826120 - J Cell Biol. 2012 Jul 23;198(2):155-64 17197698 - J Biol Chem. 2007 Feb 23;282(8):5453-67 16670339 - J Immunol. 2006 May 15;176(10 ):6277-85 22237781 - CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 15026345 - Cancer Res. 2004 Mar 15;64(6):2070-5 8665507 - Cancer Res. 1996 Jun 15;56(12):2745-7 14999148 - Breast Cancer Res Treat. 2004 Mar;84(2):183-95 14518031 - Prostate. 2003 Nov 1;57(3):245-54 2194804 - Eur J Biochem. 1990 Jun 20;190(2):427-33 24268577 - Mol Cell. 2013 Dec 26;52(6):769-82 31866 - Biochem J. 1978 Sep 15;174(3):761-8 15138577 - Int J Oncol. 2004 Jun;24(6):1369-83 12839976 - Cancer Res. 2003 Jul 1;63(13):3799-804 21726808 - Mol Cell. 2011 Jul 8;43(1):33-44 20668674 - PLoS One. 2010 Jul 26;5(7):e11776 10705076 - Nutrition. 2000 Mar;16(3):202-8 20373869 - Future Oncol. 2010 Apr;6(4):551-62 14767544 - Int J Oncol. 2004 Mar;24(3):591-608 9191002 - Hum Pathol. 1997 Jun;28(6):686-92 20167786 - Science. 2010 Feb 19;327(5968):1000-4 12796387 - Clin Cancer Res. 2003 Jun;9(6):2204-12 25053359 - Nat Rev Mol Cell Biol. 2014 Aug;15(8):536-50 17579016 - J Immunol. 2007 Jul 1;179(1):26-30 16891625 - J Lipid Res. 2006 Nov;47(11):2482-91 8710241 - Nutr Rev. 1996 Apr;54(4 Pt 1):122-3 25231933 - Oncol Rep. 2014 Dec;32(6):2471-6 11857379 - Int J Cancer. 2002 Mar 1;98(1):19-22 15814457 - IUBMB Life. 2004 Oct;56(10):595-600 15780941 - Mol Cell. 2005 Mar 18;17(6):855-68 9006336 - Am J Pathol. 1997 Jan;150(1):201-8 19608861 - Science. 2009 Aug 14;325(5942):834-40 25309810 - ACS Catal. 2014 Oct 3;4(10):3444-3453 18281474 - Cancer Res. 2008 Feb 15;68(4):1003-11 11309348 - Clin Cancer Res. 2001 Apr;7(4):971-6
References_xml	– reference: 25309810 - ACS Catal. 2014 Oct 3;4(10):3444-3453 – reference: 15138577 - Int J Oncol. 2004 Jun;24(6):1369-83 – reference: 17882277 - Nat Rev Cancer. 2007 Oct;7(10):763-77 – reference: 22826120 - J Cell Biol. 2012 Jul 23;198(2):155-64 – reference: 10095788 - Eur J Biochem. 1999 Mar;260(2):505-11 – reference: 16670339 - J Immunol. 2006 May 15;176(10 ):6277-85 – reference: 23932781 - Mol Cell. 2013 Aug 22;51(4):506-18 – reference: 14767544 - Int J Oncol. 2004 Mar;24(3):591-608 – reference: 15627654 - J Lipid Res. 2005 Apr;46(4):697-705 – reference: 12839976 - Cancer Res. 2003 Jul 1;63(13):3799-804 – reference: 19608861 - Science. 2009 Aug 14;325(5942):834-40 – reference: 23297220 - Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52 – reference: 9006336 - Am J Pathol. 1997 Jan;150(1):201-8 – reference: 26468325 - Sci Transl Med. 2015 Oct 14;7(309):309ra163 – reference: 19635858 - J Exp Med. 2009 Aug 3;206(8):1661-71 – reference: 11064454 - Oncogene. 2000 Oct 26;19(45):5173-81 – reference: 14999148 - Breast Cancer Res Treat. 2004 Mar;84(2):183-95 – reference: 8640795 - Cancer Res. 1996 Mar 15;56(6):1189-93 – reference: 11857379 - Int J Cancer. 2002 Mar 1;98(1):19-22 – reference: 24268577 - Mol Cell. 2013 Dec 26;52(6):769-82 – reference: 10962028 - Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10619-24 – reference: 8710241 - Nutr Rev. 1996 Apr;54(4 Pt 1):122-3 – reference: 20167786 - Science. 2010 Feb 19;327(5968):1000-4 – reference: 15880754 - J Pathol. 2005 Jun;206(2):214-9 – reference: 18281474 - Cancer Res. 2008 Feb 15;68(4):1003-11 – reference: 17579016 - J Immunol. 2007 Jul 1;179(1):26-30 – reference: 20373869 - Future Oncol. 2010 Apr;6(4):551-62 – reference: 12796387 - Clin Cancer Res. 2003 Jun;9(6):2204-12 – reference: 22902405 - Cell Rep. 2012 Aug 30;2(2):419-31 – reference: 18641315 - J Immunol. 2008 Aug 1;181(3):1780-6 – reference: 16891625 - J Lipid Res. 2006 Nov;47(11):2482-91 – reference: 17197698 - J Biol Chem. 2007 Feb 23;282(8):5453-67 – reference: 17956988 - Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17335-40 – reference: 31866 - Biochem J. 1978 Sep 15;174(3):761-8 – reference: 20668674 - PLoS One. 2010 Jul 26;5(7):e11776 – reference: 8665507 - Cancer Res. 1996 Jun 15;56(12):2745-7 – reference: 21726808 - Mol Cell. 2011 Jul 8;43(1):33-44 – reference: 22237781 - CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 – reference: 25231933 - Oncol Rep. 2014 Dec;32(6):2471-6 – reference: 26942676 - Mol Cell. 2016 Mar 3;61(5):720-33 – reference: 2194804 - Eur J Biochem. 1990 Jun 20;190(2):427-33 – reference: 25053359 - Nat Rev Mol Cell Biol. 2014 Aug;15(8):536-50 – reference: 10705076 - Nutrition. 2000 Mar;16(3):202-8 – reference: 11309348 - Clin Cancer Res. 2001 Apr;7(4):971-6 – reference: 15050917 - Cancer Cell. 2004 Mar;5(3):253-61 – reference: 15780941 - Mol Cell. 2005 Mar 18;17(6):855-68 – reference: 15814457 - IUBMB Life. 2004 Oct;56(10):595-600 – reference: 14518031 - Prostate. 2003 Nov 1;57(3):245-54 – reference: 9191002 - Hum Pathol. 1997 Jun;28(6):686-92 – reference: 15026345 - Cancer Res. 2004 Mar 15;64(6):2070-5
SSID	ssj0005105
Score	2.5356143
Snippet	Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	6924
SubjectTerms	Acetylation Cell Growth Processes - genetics Cell Proliferation Fatty Acid Synthases - genetics Humans Lipogenesis - genetics Signal Transduction Tumor Microenvironment
Title	Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth
URI	https://www.ncbi.nlm.nih.gov/pubmed/27758890 https://www.proquest.com/docview/1835493240
Volume	76
WOSCitedRecordID	wos000389435800018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--3w8ieI22TdMkJ1lWVwUtggp7W5JJ6ha0XW0V9t-btBVPguClh9JASSYz37y-QehEJxRk4k4gABOTmAaGCBCKWENDz5gV66BpFL7laSqGQ3nfBdyqrqzyWyc2itqU4GPkZ6GPUEhPH3c-eSN-apTPrnYjNGbRPHVQxks1H_6whbO2hLG51DyOWdfBEzLhGxgEYTGPTvu9lIQJcWad_44yG2szWPnvf66i5Q5n4l4rGGtoxhbraPGuy6RvoLF3OBt23bYPE5cZHqi6nuIe5AY_TIt67Awc1v6FradtyRy-Kca5zusKX1iclp8lvs0n5bPXl3mFVWHw48dr-Y779uUFXzkPvx5voqfB5WP_mnRTFwjEnNckikDTREuw3Bl7SKhyGESByqQNo0wrKhVQnlEGEgxLMs2YogYMcKZDmuloC80VZWF3EA6kthYUAyOVAypCuK8cHKJOr0RGJGwXHX_v4chJtU9VqMKWH9XoZxd30XZ7EKNJS78xirjzcYQM9v6weh8tOYSTtPUnB2g-c3faHqIF-Kzz6v2oERf3TO_vvgDQV8nr
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Destabilization+of+Fatty+Acid+Synthase+by+Acetylation+Inhibits+De+Novo+Lipogenesis+and+Tumor+Cell+Growth&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Lin%2C+Huai-Peng&rft.au=Cheng%2C+Zhou-Li&rft.au=He%2C+Ruo-Yu&rft.au=Song%2C+Lei&rft.date=2016-12-01&rft.issn=1538-7445&rft.eissn=1538-7445&rft.volume=76&rft.issue=23&rft.spage=6924&rft_id=info:doi/10.1158%2F0008-5472.CAN-16-1597&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7445&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7445&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7445&client=summon